Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India.
Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India.
复制标题
在印度，在印度对轻度至中度的Covid-19的现实世界经验。
DOI：
10.2147/por.s364066
复制
发表时间：
2022
影响因子：
8.9
通讯作者：
中科院分区：
文献类型：
--
作者：
法韦拉韦是一种核糖核酸依赖的核糖核酸聚合酶抑制剂(RdRp)，是一种在印度紧急使用授权批准的广谱口服抗病毒药物，用于治疗轻中度冠状病毒病(新冠肺炎)。本研究计划评估法韦拉韦在实际临床实践中的有效性和安全性。这是一项在获得独立道德委员会许可后，在印度的四个中心进行的多中心、回溯性、单臂研究。对病历进行分析，以评估服用法韦拉韦的患者的有效性和安全性。共有360名患者的病历符合纳入标准，其中358人可用于最终分析。男性占研究人群的58.46%。入选患者的平均年龄为51.80±16.45岁。最常见的症状是发热、咳嗽和肌肉酸痛-疲劳。临床治愈和退烧的中位时间分别为5天和4天。平均住院时间为6天。总体而言，8%的患者经历了不良事件。肝酶升高、腹泻、食欲减退、头痛、乏力、头晕为常见症状。在我们的真实研究中，法韦拉韦在轻中度新冠肺炎患者中的临床治愈率超过90%。这支持了法韦拉韦在新冠肺炎治疗中的应用。法维拉韦耐受性良好，副作用极小，本质上是暂时性的。
Favipiravir, an RNA-dependent RNA polymerase inhibitor (RdRp), is a broad-spectrum oral antiviral agent approved in India under emergency use authorization, for the treatment of mild-to-moderate coronavirus disease (COVID-19). The present study was planned to evaluate the effectiveness and safety of favipiravir in real-world clinical practice. This was a multicentric, retrospective, single-arm study conducted across four centres in India, after obtaining permission from the independent ethics committee. Medical records were analysed to evaluate effectiveness and safety of patients who were prescribed favipiravir. The medical records of a total of 360 patients met the inclusion criteria, with 358 of them available for the final analysis. Males made up 58.46% of the study population. The average age of enrolled patients was 51.80 ± 16.45 years. The most common symptoms were fever, cough, and myalgia-fatigue. The median time to clinical cure and fever relief was five and four days, respectively. The average length of stay in the hospital was six days. In total, 8% of the patients experienced adverse events. Hepatic enzyme elevation, diarrhoea, decreased appetite, headache, fatigue, and giddiness were the common symptoms. In our real-world study, favipiravir was found to have a clinical cure rate of more than 90% in mild-to-moderate COVID-19 patients. This supports the use of favipiravir in the treatment of COVID-19. Favipiravir was well tolerated, with only minimal side effects, which were transient in nature.